MESO
Mesoblast Ltd
NASDAQ: MESO · HEALTHCARE · BIOTECHNOLOGY
$13.10
-4.03% today
Updated 2026-11-12
Market cap
$1.82B
P/E ratio
—
P/S ratio
15.11x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$12 – $22
Volume
0.2M
Mesoblast Ltd (MESO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$13.10
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$57.02
Financial forecast
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -47.80%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.